Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3 - Should we avoid amino acid sequence polymorphisms or embrace them?

Journal of Infectious Diseases

Volumn 195, Issue 2, 2007, Pages 171-173

  Saul, Allan ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; GENETIC POLYMORPHISM; INFECTION PREVENTION; INNATE IMMUNITY; MEROZOITE; NOTE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; PROTOZOAN PROTEINS;

EID: 33846129088     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/509813     Document Type: Note

References (18)

1. Good MF. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 2005; 21:29-34.
2. Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004; 71:239-47.
3. Kennedy MC, Wang J, Zhang Y, et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 2002; 70:6948-60.
4. Dvorak JA, Miller LH, Whitehouse WC, Shiroishi T. Invasion of erythrocytes by malaria merozoites. Science 1975; 187:748-50.
5. Saul A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 1987; 9:1-9.
6. McColl DI, Silva A, Foley M, et al. Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol 1994; 68:53-67.
7. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182:409-18.
8. Oeuvray C, Bouharoun TH, Gras MH, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84:1594-602.
9. Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004; 190:1010-8.
10. Hisaeda H, Saul A, Reece JJ, et al. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002; 185:657-64.
11. Carvalho LJ, Oliveira SG, Theisen M, et al. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 2004; 59:363-72.
12. Meraldi V, Nebie I, Tiono AB, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004; 26:265-72.
13. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004; 72:247-52.
14. Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017-26.
15. Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005; 2:e344.
16. Polley SD, Tetteh KKA, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007; 195:279-87 (in this issue).
17. Huber W, Felger I, Matile H, Lipps HJ, Steiger S, Beck HP. Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem Parasitol 1997; 87:231-4.
18. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73:3677-85.